Randomised Phase II Study to Assess the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schedules (rAd26-rAd5, rAd26-rAd26, rAd26-ChAdOx1 and rAd26-mRNA-1273)
Latest Information Update: 07 Aug 2023
At a glance
- Drugs AZD 1222 (Primary) ; COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary) ; Elasomeran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 07 Sep 2021 New trial record